WO2024076864A2 - Anticorps anti-ror1 et leurs utilisations - Google Patents

Anticorps anti-ror1 et leurs utilisations Download PDF

Info

Publication number
WO2024076864A2
WO2024076864A2 PCT/US2023/075332 US2023075332W WO2024076864A2 WO 2024076864 A2 WO2024076864 A2 WO 2024076864A2 US 2023075332 W US2023075332 W US 2023075332W WO 2024076864 A2 WO2024076864 A2 WO 2024076864A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
light chain
Prior art date
Application number
PCT/US2023/075332
Other languages
English (en)
Other versions
WO2024076864A3 (fr
Inventor
Huiwen WU
Haiqun JIA
Hui Zou
Original Assignee
Phanes Therapuetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapuetics, Inc. filed Critical Phanes Therapuetics, Inc.
Publication of WO2024076864A2 publication Critical patent/WO2024076864A2/fr
Publication of WO2024076864A3 publication Critical patent/WO2024076864A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • This invention relates to monoclonal anti-RORl antibodies, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and compositions comprising the antibodies.
  • Methods of making the antibodies, and methods of using the antibodies to treat diseases including cancer, inflammatory diseases, autoimmune diseases, and/or associated complications are also provided.
  • Tyrosine-protein kinase transmembrane receptor ROR1 also known as neurotrophic tyrosine kinase, receptor-related 1(NTRKR1), is a member of the receptor tyrosine kinase-like orphan receptor (ROR) family.
  • ROR1 is a transmembrane receptor that contains an extracellular domain, a transmembrane domain, and a cytoplasmic domain. The extracellular domain modulates non-canomcal WNT signaling by binding to the ligand Wnt5a (Yu J., et al. J Clin Invest. 2016, 126(2):585-98).
  • ROR1 regulates several cellular processes including cell division, proliferation, migration, and chemotaxis.
  • ROR1 is strongly expressed during fetal and embryonic development. It plays an essential role in embryogenesis (Cui B., et al. Cancer Res. 2013, (12):3649-60). Its expression is much reduced and in only limited tissues of healthy adults.
  • ROR1 Aberrant expression of ROR1 is strongly linked to advanced disease progression and chemoresistance (Zhao Y., et al. Front Oncol., 2021 (11), 680834:1-8). Many studies have shown that ROR1 is highly expressed in malignant cells, including, but not limited to, chronic lymphocytic leukemia (CLL), B acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), ovarian cancer, breast cancer, and hepatocellular carcinoma (Cui B.. et al. Blood 2016, 128(25):2931- 2940; Zhang S favor et al.
  • CLL chronic lymphocytic leukemia
  • B-ALL B acute lymphoblastic leukemia
  • MCL mantle cell lymphoma
  • AML acute myeloid leukemia
  • NHL non-Hodgkin lymphoma
  • ROR1 plays an important role in oncogenesis and cancer stem cell survival and epithelial-mesenchymal transition. Studies in breast cancer suggested that RORl-mediated PI3K/AKT/CREB signaling contributed to the growth and survival of breast cancer cells and this signaling activity was augmented upon stimulation by Wnt5a development (Zhang S., et al., PLOS ONE. 2012, 7(3): e31127). [0006] Because of the low and limited expression of ROR1 in healthy adults and high expression on the surface cancer cells, ROR1 is a good target for treating cancers with elevated levels of ROR1.
  • the invention relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind ROR1.
  • isolated monoclonal antibodies or antigen-binding fragments thereof comprising a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:
  • the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1, 15, 29, 58, 72, 86, 100, 114, 128, or 142, or a light chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 2, 16, 30, 59, 73, 87, 101, 115, 129, or 143.
  • the isolated monoclonal antibody or antigen-binding fragment thereof comprises:
  • the isolated monoclonal antibody or antigen-binding fragment thereof binds to RORI and is capable of inducing effector-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), antibody -dependent cellular phagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC); and/or mediating the recruitment of conjugated drugs; and/or forming a bispecific antibody with another monoclonal antibody or antigen-binding fragment thereof with cancer-killing effect.
  • ADCC antibody-dependent cellular cytotoxicity
  • ADCP antibody -dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • the isolated monoclonal antibody or antigen-binding fragment thereof is chimeric.
  • the isolated monoclonal antibody or antigen-binding fragment thereof is human or humanized.
  • the humanized monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 43-50, or a light chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 51-57.
  • the humanized monoclonal antibody or antigen-binding fragment thereof comprises:
  • (21) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:45, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 57;
  • (31) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 53;
  • (32) a heavy 7 chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 54;
  • isolated bispecific antibodies comprising the monoclonal antibodies or antigen-binding fragments thereof of the invention.
  • isolated nucleic acids encoding the monoclonal antibodies or antigen-binding fragments thereof or bispecific antibodies of the invention.
  • vectors comprising the isolated nucleic acids encoding the monoclonal antibodies or antigen-binding fragments thereof or bispecific antibodies or antigen-binding fragments thereof of the invention.
  • host cells comprising the vectors comprising the isolated nucleic acids encoding the monoclonal antibodies or antigen-binding fragments thereof or bispecific antibodies or antigen-binding fragments thereof of the invention.
  • a pharmaceutical composition comprising an isolated monoclonal antibody or antigen-binding fragment thereof or an isolated bispecific antibody or antigen-binding fragment thereof of the invention and a pharmaceutically acceptable carrier.
  • the cancer can be any liquid or solid cancer, for example, it can be selected from, but not limited to, a lung cancer, a gastric cancer, an esophageal cancer, a bile duct cancer, a cholangiocarcinoma, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a chronic mye
  • NHL acute lymphocytic leukemia
  • CLL chronic lymphocytic leukemia
  • Also provided are methods of producing a monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof of the invention comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof under conditions to produce the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof, and recovering the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof from the cell or culture.
  • Also provided are methods of producing a pharmaceutical composition comprising a monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigenbinding fragment thereof of the invention, comprising combining the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.
  • kits for determining the level of ROR1 in a subject comprise (a) obtaining a sample from the subject; (b) contacting the sample with an antibody or antigen-binding fragment thereof of the invention; and (c) determining the level of ROR1 in the subject.
  • the sample is a tissue sample.
  • the tissue sample can, for example, be a cancer tissue sample.
  • the sample is a blood sample.
  • the invention relates to a chimeric antigen receptor (CAR) construct that induces T cell mediated cancer killing, wherein the CAR construct comprises at least one antigen binding domain that specifically binds human ROR1, a hinge region, a transmembrane region, and an intracellular signaling domain.
  • CAR chimeric antigen receptor
  • isolated polynucleotides comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR).
  • the CAR can, for example, comprise (a) an extracellular domain comprising at least one antigen binding domain that specifically binds ROR1: (b) a hinge region; (c) a transmembrane region; and (d) an intracellular signaling domain.
  • the antigen binding domain comprises a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region comprising a light chain complementarity’ determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:
  • the antigen binding domain comprises a heavy chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1, 15, 29, 58, 72, 86, 100, 114, 128, or 142, or a light chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 2, 16, 30, 59, 73, 87, 101, 115, 129, or 143.
  • the antigen binding domain comprises:
  • the antigen binding domain is humanized and comprises a heavy chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 43-50, or a light chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 51-57.
  • the antigen binding domain is humanized and comprises:
  • (31) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 53;
  • (32) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 54;
  • the antigen binding domain is a single chain variable fragment (scFv).
  • the antigen binding domain is a humanized single chain variable fragment (scFv).
  • the chimeric antigen receptor comprises one or more antigen binding domains.
  • the intracellular signaling domain comprises one or more costimulatory domains and one or more activating domains.
  • CARs chimeric antigen receptors
  • vectors comprising the isolated polynucleotides comprising nucleic acids encoding the CARs of the invention.
  • host cells comprising the vectors of the invention.
  • the host cell is a T cell, preferably a human T cell.
  • the host cell is a NK cell, preferably a human NK cell.
  • the T cell or NK cell can, for example, be engineered to express the CAR of the invention to treat diseases such as cancer.
  • the methods comprise transducing a T cell or a NK cell with a vector comprising the isolated nucleic acids encoding the CARs of the invention.
  • methods of producing a CAR-T cell or CAR-NK cell of the invention comprise culturing T cells or NK cells comprising the isolated polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR) of the invention under conditions to produce the CAR-T cell or CAR-NK cell and recovering the CAR-T cell or CAR-NK cell.
  • the methods comprise contacting a cell with the isolated polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR) of the invention, wherein the isolated polynucleotide is an in vitro transcribed RNA or synthetic RNA.
  • the cancer can be any liquid or solid cancer, for example, it can be selected from, but not limited to, a lung cancer, a gastric cancer, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a chronic myelogenous leukemia (CML), a multiple myeloma
  • NHL acute lymphocytic leukemia
  • CLL chronic lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • the methods of treating cancer in a subject in need thereof further comprise administering to the subject in need thereof an agent that increases the efficacy of a cell expressing a CAR molecule.
  • the methods of treating cancer in a subject in need thereof further comprise administering to the subject in need thereof an agent that ameliorates one or more side effects associated with administration of a cell expressing a CAR molecule.
  • the methods of treating cancer in a subject in need thereof further comprise administering to the subject in need thereof an agent that treats the disease associated with ROR1.
  • FIGs. 1 A-1E show the binding of purified chimeric anti-RORl mAbs (VH and VL regions of mouse mAb fused to the constant regions of human IgGl heavy chain and kappa light chain, respectively) to immobilized recombinant ROR1 in an ELISA assay.
  • the recombinant human ROR1 contains the extracellular region of AA Gin 30- Glu 403, carrying a 6xHis at the C-terminus (ACROBiosystems, CAT#: R01-H522y-100p.g;
  • Isotype control (IgGl) was added in the assay as a negative control antibody.
  • FIGs. 2A-2C show the binding of anti-RORl mAb to KLE cell line (ATCC, CAT#: CRL-1622) using FACS analysis.
  • Isotype control IgGl was added as a negative control antibody.
  • FIGs. 3A-3D show the binding of purified humanized anti-RORl mAbs to immobilized recombinant ROR1 in an ELISA assay.
  • the recombinant human ROR1 contains extracellular region of AA Gin 30- Glu 403, carrying a 6xHis at the C-terminus (AcroBiosystems, CAT#: R01-H522y-100pg).
  • any numerical values such as a concentration or a concentration range described herein, are to be understood as being modified in all instances by the term “about.”
  • a numerical value typically includes ⁇ 10% of the recited value.
  • a concentration of 1 mg/mL includes 0.9 mg/mL to 1. 1 mg/mL.
  • a concentration range of 1% to 10% (w/v) includes 0.9% (w/v) to 11% (w/v).
  • the use of a numerical range expressly includes all possible subranges, all individual numerical values within that range, including integers within such ranges and fractions of the values unless the context clearly indicates otherwise.
  • the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains” or “containing,” or any other variation thereof, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers and are intended to be non-exclusive or open-ended.
  • a composition, a mixture, a process, a method, an article, or an apparatus that comprises a list of elements is not necessarily limited to only those elements but can include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.
  • “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
  • the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and/or.”
  • subject means any animal, preferably a mammal, most preferably a human.
  • mammal encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., more preferably a human.
  • nucleic acids or polypeptide sequences e.g., anti-RORl antibodies and polynucleotides that encode them, chimeric antigen receptors (CARs) comprising antigen binding domains specific for R0R1 and polynucleotides that encode them
  • CARs chimeric antigen receptors
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • sequence comparison algorithm calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
  • Optimal alignment of sequences for comparison can be conducted, e.g.. by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 1981; 2:482, by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 1970; 48:443, by the search for similarity method of Pearson & Lipman, Proc. Nat’l. Acad. Sci. USA 1988; 85:2444, by computerized implementations of these algorithms (GAP. BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology 7 , F.M.
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
  • HSPs high scoring sequence pairs
  • Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always ⁇ 0).
  • M forward score for a pair of matching residues; always > 0
  • N penalty score for mismatching residues; always ⁇ 0.
  • a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negativescoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity 7 and speed of the alignment.
  • W wordlength
  • E expectation
  • the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 1989; 89: 10915).
  • the BLAST algorithm In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat’l. Acad. Sci. USA 1993; 90:5873-5787).
  • One measure of similarity 7 provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • a nucleic acid is considered similar to a reference sequence if the smallest sum probability 7 in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • a further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below.
  • a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.
  • Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.
  • isolated means a biological component (such as a nucleic acid, peptide or protein) has been substantially separated, produced apart from, or purified away from other biological components of the organism in which the component naturally occurs, i.e., other chromosomal and extrachromosomal DNA and RNA, and proteins.
  • Nucleic acids, peptides and proteins that have been “isolated” thus include nucleic acids and proteins purified by standard purification methods. "Isolated" nucleic acids, peptides and proteins can be part of a composition and still be isolated if the composition is not part of the native environment of the nucleic acid, peptide, or protein. The term also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
  • polynucleotide synonymously referred to as “nucleic acid molecule,” “nucleotides” or “nucleic acids,” refers to any polyribonucleotide or poly deoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA.
  • Polynucleotides include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
  • polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
  • Modified bases include, for example, tritylated bases and unusual bases such as inosine.
  • polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
  • Polynucleotide also embraces relatively short nucleic acid chains, often referred to as oligonucleotides.
  • the term “vector” is a replicon in which another nucleic acid segment can be operably inserted so as to bring about the replication or expression of the segment.
  • the term “host cell” refers to a cell comprising a nucleic acid molecule of the invention.
  • the “host cell” can be any type of cell, e.g., a primary cell, a cell in culture, or a cell from a cell line.
  • a “host cell” is a cell transfected with a nucleic acid molecule of the invention.
  • a “host cell” is a progeny or potential progeny of such a transfected cell.
  • a progeny of a cell may or may not be identical to the parent cell, e.g., due to mutations or environmental influences that can occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.
  • the term encompasses the transcription of a gene into RNA.
  • the term also encompasses translation of RNA into one or more polypeptides, and further encompasses all naturally occurring post-transcriptional and post-translational modifications.
  • the expressed antibody can be within the cytoplasm of a host cell, into the extracellular milieu such as the growth medium of a cell culture or anchored to the cell membrane.
  • the terms “peptide,” “polypeptide,” or “protein” can refer to a molecule comprised of amino acids and can be recognized as a protein by those of skill in the art.
  • polypeptide can be used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids.
  • the terms also encompass an ammo acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • chimeric antigen receptor refers to a recombinant polypeptide comprising at least an extracellular domain that binds specifically to an antigen or a target, a transmembrane domain and an intracellular T cell receptor-activating signaling domain. Engagement of the extracellular domain of the CAR with the target antigen on the surface of a target cell results in clustering of the CAR and delivers an activation stimulus to the CAR-containing cell. CARs redirect the specificity of immune effector cells and trigger proliferation, cytokine production, phagocytosis and/or production of molecules that can mediate cell death of the target antigen-expressing cell in a major histocompatibility (MHC)- independent manner.
  • MHC major histocompatibility
  • signal peptide' refers to a leader sequence at the aminoterminus (N-terminus) of a nascent CAR protein, which co-translationally or post- translationally directs the nascent protein to the endoplasmic reticulum and subsequent surface expression.
  • extracellular antigen binding domain refers to the part of a CAR that is located outside of the cell membrane and is capable of binding to an antigen, target, or ligand.
  • the term “hinge region” refers to the part of a CAR that connects two adjacent domains of the CAR protein, e.g., the extracellular domain and the transmembrane domain.
  • transmembrane domain refers to the portion of a CAR that extends across the cell membrane and anchors the CAR to cell membrane. It is sometimes referred to as “transmembrane region”.
  • chimeric antigen receptors can incorporate costimulatory (signaling) domains to increase their potency.
  • a costimulatory (signaling) domain can be derived from a costimulatory molecule.
  • Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an efficient immune response.
  • Costimulatory domains can be derived from costimulatory molecules, which can include, but are not limited to, CD28, CD28T, 0X40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9, CD1 , CD22, CD27, CD30, CD33, CD37, CD40, CD45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen- 1 (LFA-1; CD1 la and CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NK.G2C, Ig alpha (CD79a), DAP10, Fc gamma receptor, MHC class I molecule, TNFR, integrin, signaling lymphocytic
  • CD49f. ITGAD, ITGAE, CD103, ITGAL, CDla, CDlb, CDlc, CDld, ITGAM, ITGAX, ITGB1, CD29, ITGB2 (CD18), ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD 160 (BY55), PSGL1.
  • CD 100 SEMA4D
  • CD69 SLAMF6
  • NTB-A SLAMF6
  • SLAM SLAMF1, CD150, IPO-3
  • BLAME SLAMF8
  • SELPLG CD162
  • LTBR LAT
  • GADS GADS
  • SLP-76 PAG/Cbp
  • CD 19a CD83 ligand, cytokine receptor, activating NK cell receptors, or fragments or any combination thereof.
  • chimeric antigen receptors can comprise activating domains.
  • Activating domains can include, but are not limited to, CD3.
  • CD3 is an element of the T cell receptor on native T cells and has been show n to be an important intracellular activating element in CARs.
  • the CD3 is CD3 zeta.
  • the chimeric antigen receptor can comprise a hinge region. This is a portion of the extracellular domain, sometimes referred to as a ‘‘spacer"’ region.
  • hinges can be employed in accordance with the invention, including costimulatory molecules, as discussed above, immunoglobulin (Ig) sequences, or other suitable molecules to achieve the desired special distance from the target cell.
  • Ig immunoglobulin
  • the entire extracellular region comprises a hinge region.
  • chimeric antigen receptors can comprise a transmembrane region/domain.
  • the CAR can be designed to comprise a transmembrane domain that is fused to the extracellular domain of the CAR. It can similarly be fused to the intracellular domain of the CAR.
  • the transmembrane domain that is naturally associated with one of the domains in a CAR is used.
  • the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
  • the transmembrane domain may be derived either from a natural or from a synthetic source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein.
  • Transmembrane regions of particular use in this invention can be derived from (i.e., comprise or engineered from), but are not limited to, CD28, CD28T, 0X40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9. CD 16, CD22, CD27, CD30, CD33, CD37. CD40. CD45, CD64, CD80. CD86, CD134. CD137, CD154.
  • PD-1 programmed death-1
  • ICOS inducible T cell costimulator
  • LFA-1 lymphocyte function-associated antigen-1
  • CD247 CD276 (B7-H3)
  • LIGHT tumor necrosis factor superfamily member 14
  • NKG2C Ig alpha (CD79a)
  • DAP10 Fc gamma receptor.
  • MHC class I molecule TNFR. integrin, signaling Ivmphoc tic activation molecule, BTLA, Toll ligand receptor, ICAM-1, CDS, GITR, BAFFR, LIGHT, HVEM (LIGHTR).
  • CD 100 SEMA4D
  • CD69 SLAMF6
  • NTB-A SLAMF6
  • SLAM SLAMF1, CD150, IPO-3
  • BLAME SLAMF8
  • SELPLG CD 162
  • LTBR LAT
  • GADS GADS
  • SLP-76 PAG/Cbp
  • CD 19a CD83 ligand
  • cytokine receptor activating NK cell receptors, an immunoglobulin protein, or fragments or any combination thereof.
  • the invention provides cells that are immune cells that comprise the isolated polynucleotides or vectors comprising the isolated polynucleotides comprising the nucleotide sequences encoding the CARs are provided herein.
  • the immune cells comprising the isolated polynucleotides and/or vectors of the invention can be referred to as "engineered immune cells.”
  • the engineered immune cells are derived from a human (are of human origin prior to being made recombinant).
  • the engineered immune cells can, for example, be cells of the lymphoid lineage.
  • Non-limiting examples of cells of the lymphoid lineage can include T cells and Natural Killer (NK) cells.
  • T cells express the T cell receptor (TCR), with most cells expressing a and chains and a smaller population expressing y and 8 chains.
  • T cells useful as engineered immune cells of the invention can be CD4 + or CD8 + and can include, but are not limited to, T helper cells (CD4 + ), cytotoxic T cells (also referred to as cytotoxic T lymphocytes.
  • CTL CD8 + cells
  • memory T cells including central memory T cells, stem-like memory T cells, and effector memory T cells, natural killer T cells, mucosal associated invariant T cells, and y8 T cells.
  • Other exemplary immune cells include, but are not limited to, macrophages, antigen presenting cells (APCs), or any immune cell that expresses an inhibitor of a cell- mediated immune response, for example, an immune checkpoint inhibitor pathway receptor (e.g., PD-1).
  • Precursor cells of immune cells that can be used according to the invention include, hematopoietic stem and/or progenitor cells.
  • Hematopoietic stem and/or progenitor cells can be derived from bone marrow, umbilical cord blood, adult peripheral blood after cytokine mobilization, and the like, by methods known in the art.
  • the immune cells are engineered to recombinantly express the CARs of the invention.
  • Immune cells and precursor cells thereof can be isolated by methods know n in the art, including commercially available methods (see, e.g., Rowland Jones et al., Lymphocytes: A Practical Approach, Oxford University Press, NY 1999).
  • Sources for immune cells or precursors thereof include, but are not limited to, peripheral blood, umbilical cord blood, bone marrow, or other sources of hematopoietic cells.
  • Various techniques can be employed to separate the cells to isolated or enrich desired immune cells. For instance, negative selection methods can be used to remove cells that are not the desired immune cells. Additionally, positive selection methods can be used to isolate or enrich for the desired immune cells or precursors thereof, or a combination of positive and negative selection methods can be employed. If a particular type of cell is to be isolated, e.g., a particular T cell, various cell surface markers or combinations of markers (e.g., CD3, CD4. CD8. CD34) can be used to separate the cells.
  • markers or combinations of markers e.g., CD3, CD4. CD8. CD34
  • the immune cells or precursor cells thereof can be autologous or non-autologous to the subject to which they are administered in the methods of treatment of the invention.
  • Autologous cells are isolated from the subject to which the engineered immune cells recombinantly expressing the CAR are to be administered.
  • the cells can be obtained by leukapheresis, where leukocytes are selectively removed from withdraw ! blood, made recombinant, and then retransfused into the donor.
  • allogeneic cells from a non-autologous donor that is not the subject can be used.
  • the cells are typed and matched for human leukocyte antigen (HLA) to determine the appropriate level of compatibility.
  • HLA human leukocyte antigen
  • the cells can optionally be cryopreserved until ready for use.
  • Various methods for isolating immune cells that can be used for recombinant expression of the CARs of the invention have been described previously, and can be used, including, but not limited to, using peripheral donor lymphocytes (Sadelain et al., Nat. Rev. Cancer 2003; 3:35-45; Morgan et al., Science 2006; 314: 126-9), using lymphocyte cultures derived from tumor infiltrating lymphocytes (TILs) in tumor biopsies (Panelli et al., J. Immunol. 2000; 164:495-504; Panelli et al., J. Immunol.
  • TILs tumor infiltrating lymphocytes
  • AAPCs artificial antigen-presenting cells
  • dendritic cells Dendritic cells
  • stem cells the cells can be isolated by methods well known in the art (see, e.g.. Klug et al., Hematopoietic Stem Cell Protocols, Humana Press, NJ 2002; Freshney et al.. Culture of Human Stem Cells, John Wiley & Sons 2007).
  • the method of making the engineered immune cells comprises transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells express one or more CAR(s) according to embodiments of the invention.
  • Methods of preparing immune cells for immunotherapy are described, e.g., in WO2014/130635, WO2013/176916 and WO2013/176915, which are incorporated herein by reference.
  • Individual steps that can be used for preparing engineered immune cells are disclosed, e.g.. in WO2014/039523.
  • WO2014/184744 and WO2014/184143 which are incorporated herein by reference.
  • the immune effector cells such as T cells
  • T cells can be activated and expanded before or after genetic modification to express a CAR, using methods as described, for example, in US6352694, US6534055, US6905680, US6692964, US5858358, US6887466, US6905681, US7144575, US7067318, US7172869, US7232566, US7175843, US5883223, US6905874.
  • T cells can be expanded in vitro or in vivo.
  • the T cells of the invention can be expanded by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex-associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the T cells.
  • an agent that stimulates a CD3/TCR complex-associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the T cells As nonlimiting examples.
  • T cell populations can be stimulated as described herein, such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD3 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore, or by activation of the CAR itself.
  • a protein kinase C activator e.g., bryostatin
  • a ligand that binds the accessory molecule is used for co-stimulation of an accessory molecule on the surface of the T cells.
  • a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells.
  • Conditions appropriate for T cell culture include, e.g., an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5 (Lonza)) that can contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), cytokines, such as IL-2, IL-7, IL-15, and/or IL-21, insulin, IFN-g, GM-CSF, TGF
  • an appropriate media e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5 (Lonza)
  • serum e.g., fetal bovine or human serum
  • cytokines such as IL-2, IL-7, IL-15, and/or IL-21
  • insulin IFN-g
  • GM-CSF TGF
  • 3 TGF
  • the T cells can be activated and stimulated to proliferate with feeder cells and appropriate antibodies and cytokines using methods such as those described in US6040177, US5827642, and WO2012129514, which are incorporated herein by reference.
  • the invention generally relates to isolated anti-RORl antibodies, chimeric antigen receptors (CARs), nucleic acids and expression vectors encoding the antibodies and CARs, recombinant cells containing the vectors, and compositions comprising the antibodies, CARs, and recombinant cells expressing the CARs.
  • the antibodies and antigen binding domains of the CARs of the invention possess one or more desirable functional properties, including, but not limited to. high-affinity binding to ROR1, high specificity to ROR1.
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • ADCC antibody-dependent cellular-mediated cytotoxicity
  • the invention relates to isolated monoclonal antibodies or antigenbinding fragments thereof that bind ROR1.
  • antibody is used in a broad sense and includes immunoglobulin or antibody molecules including human, humanized, composite and chimeric antibodies and antibody fragments that are monoclonal or polyclonal. In general, antibodies are proteins or peptide chains that exhibit binding specificity’ to a specific antigen. Antibody structures are well known. Immunoglobulins can be assigned to five major classes (i.e., IgA, IgD, IgE, IgG and IgM), depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub-classified as the isotypes IgAl, IgA2. IgGl, IgG2, IgG3 and IgG4.
  • the antibodies of the invention can be of any of the five major classes or corresponding sub-classes.
  • the antibodies of the invention are IgGl, IgG2, IgG3 or IgG4.
  • Antibody light chains of vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains.
  • the antibodies of the invention can contain a kappa or lambda light chain constant domain.
  • the antibodies of the invention include heavy and/or light chain constant regions from rat or human antibodies.
  • antibodies contain an antigen-binding region that is made up of a light chain variable region and a heavy chain variable region, each of which contains three domains (i.e., complementarity determining regions 1-3; CDR1, CDR2, and CDR3).
  • the light chain variable region domains are alternatively referred to as LCDR1, LCDR2, and LCDR3, and the heavy chain variable region domains are alternatively referred to as HCDR1, HCDR2, and HCDR3.
  • CDR CDRs defined by any of the methods described supra, Kabat, Chothia, IMGT or AbM, unless otherwise explicitly stated in the specification.
  • CDRs defined by any of the methods described supra, Kabat, Chothia, IMGT or AbM, unless otherwise explicitly stated in the specification.
  • the numbering system including, for example, the Kabat numbering and the IMGT unique numbering system, is well known to one skilled in the art (see, e.g., Kabat; Chothia; Martin; Lefranc et al.).
  • Table A CDR determinations by different methods. substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to ROR1 is substantially free of antibodies that do not bind to the same ROR1). In addition, an isolated antibody is substantially free of other cellular material and/or chemicals.
  • the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.
  • the monoclonal antibodies of the invention can be made by the hybridoma method, phage display technology, single lymphocyte gene cloning technology, or by recombinant DNA methods.
  • the monoclonal antibodies can be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, such as a transgenic mouse or rat, having a genome comprising a human heavy chain transgene and a light chain transgene.
  • the term ‘"antigen-binding fragment” and/or "‘antigen binding domain” refers to an antibody fragment such as, for example, a diabody, a Fab, a Fab', a F(ab')2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)z, a bispecific dsFv (dsFv-dsFv 1 ), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), a single domain antibody (sdab) an scFv dimer (bivalent diabody), a multispecific antibody formed from a portion of an antibody comprising one or more CDRs, a camelized single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not comprise a complete antibody structure.
  • an antibody fragment such as, for example,
  • an antigen-binding fragment is capable of binding to the same antigen to which the parent antibody or a parent antibody fragment binds.
  • the antigen-binding fragment comprises a light chain variable region, a light chain constant region, and an Fd segment of the heavy chain.
  • the antigen-binding fragment comprises Fab and F(ab’).
  • An antigen binding domain is capable of binding to the same antigen to which the parent antibody binds.
  • the antigen binding domain comprises a single-chain antibody molecule (scFv).
  • single-chain antibody refers to a conventional singlechain antibody in the field, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids.
  • single domain antibody refers to a conventional single domain antibody in the field, which comprises a heavy chain variable region and a heavy' chain constant region or which comprises only a heavy chain variable region.
  • human antibody refers to an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human made using any technique known in the art. This definition of a human antibody includes intact or full-length antibodies, fragments thereof, and/or antibodies comprising at least one human heavy and/or light chain polypeptide.
  • humanized antibody and/or “humanized antigen binding domain” refers to a non-human antibody and/or non-human antigen binding domain that is modified to increase the sequence homolog ⁇ ' to that of a human antibody and/or a human antigen binding domain, such that the antigen-binding properties of the antibody and/or antigen binding domain are retained, but its antigenicity in the human body is reduced.
  • chimeric antibody and/or “chimeric antigen binding domain” refers to an antibody and/or antigen binding domain wherein the amino acid sequence of the immunoglobulin molecule is derived from two or more species.
  • variable region of both the light and heavy chains often corresponds to the variable region of an antibody and/or antigen binding domain derived from one species of mammal (e.g., mouse, rat, rabbit, etc.) having the desired specificity, affinity, and capability, while the constant regions correspond to the sequences of an antibody and/or antigen binding domain derived from another species of mammal (e.g., human) to avoid eliciting an immune response in that species.
  • mammal e.g., mouse, rat, rabbit, etc.
  • constant regions correspond to the sequences of an antibody and/or antigen binding domain derived from another species of mammal (e.g., human) to avoid eliciting an immune response in that species.
  • multi-specific antibody refers to an antibody that comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope.
  • the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein).
  • the first and second epitopes overlap or substantially overlap.
  • the first and second epitopes do not overlap or do not substantially overlap.
  • the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein).
  • a multi-specific antibody comprises a third, fourth, or fifth immunoglobulin variable domain.
  • a multi-specific antibody is a bispecific antibody molecule, a tri-specific antibody molecule, or a tetra-specific antibody molecule.
  • bispecific antibody refers to a multi-specific antibody that binds no more than two epitopes or two antigens.
  • a bispecific antibody is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.
  • the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein).
  • the first and second epitopes overlap or substantially overlap.
  • the first and second epitopes are on different antigens, e.g, different proteins (or different subunits of a multimeric protein).
  • a bispecific antibody comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope.
  • a bispecific antibody comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope.
  • a bispecific antibody comprises a scFv, or fragment thereof, having binding specificity for a first epitope, and a scFv. or fragment thereof, having binding specificity for a second epitope.
  • the first epitope is located on R0R1 of this invention and the second epitope is located on PD-1, PD-L1, TIM- 3, LAG-3, CTLA-4, EGFR, HER-2, CD19, CD20, CD33.
  • first and the second epitopes are located on the same R0R1 of this invention.
  • an antibody and/or antigen binding domain that "‘specifically binds to R0R1’’ refers to an antibody and/or antigen binding domain that binds to R0R1, preferably the human ROR1, with a KD of 1 x ICT 7 M or less, preferably 1 * ICT 8 M or less, more preferably 5 / 10 9 M or less, 1 1 9 M or less, 5 z 10 10 M or less, or P I O 10 M or less.
  • KD refers to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e., Kd/Ka) and is expressed as a molar concentration (M).
  • KD values for antibodies and/or antigen binding domains can be determined using methods in the art in view of the present disclosure.
  • the KD of an antibody and/or antigen binding domains can be determined by using surface plasmon resonance, such as by using a biosensor system, e.g., a BIACORE® system, or by using bio-layer interferometry technology, such as an Octet RED96 system.
  • IC50 refers to the half maximal inhibitory concentration of a monoclonal or bispecific antibody or antigen-binding fragment thereof of the invention. IC50 is a measure of the potency of the monoclonal or bispecific antibody or antigen-binding fragment thereof of the invention for inhibiting the binding of the target antigen (i.e., a receptor or ligand) with its natural ligand or receptor or inhibiting the function of the target antigen in a cell.
  • target antigen i.e., a receptor or ligand
  • the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof has a KD of less than about 10‘ 7 M, less than about 10’ 8 M. less than about 10' 9 M, less than about IO' 10 M, less than about 10’ 11 M, less than about 10 12 M, or less than about 10 13 M.
  • EC50 refers to the half maximal effective concentration of a monoclonal or bispecific antibody or antigen-binding fragment thereof or a CAR comprising an antigen-binding domain of the invention. EC50 refers to the concentration of a monoclonal or bispecific antibody or antigen-binding fragment thereof or the CAR comprising the antigen-binding domain for inducing a biological response (i. e. , cell death) halfway between the baseline and maximum over a specified exposure time.
  • a biological response i. e. , cell death
  • the monoclonal antibody or antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment thereof, or the CAR comprising the antigen-binding domain has an EC 50 of less than about 1 p.M, about 1000 nM to about 100 nM, about 100 nM to about 10 nM, about 10 nM to about 1 nM, about 1000 pM to about 500 pM, about 500 pM to about 200 pM, less than about 200 pM, about 200 pM to about 150 pM, about 200 pM to about 100 pM, about 100 pM to about 10 pM, or about 10 pM to about 1 pM.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or a chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the monoclonal antibody or antigen-binding fragment thereof or antigen binding domain comprises a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, a HCDR3, and a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, having the polypeptide sequences of:
  • SEQ ID NOs: 144, 145, 146, 147, 148, and 149 respectively, or SEQ ID NOs: 150, 151, 152, 153, 154, and 155, respectively; wherein the antibody or antigen-binding fragment thereof or antigen binding domain thereof specifically binds ROR1, preferably human ROR1.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or a chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the monoclonal antibody or antigenbinding fragment thereof or antigen binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NO: 1, 15, 29, 58, 72, 86, 100, 114. 128, or 142, or a light chain variable region having a polypeptide sequence at least 85%.
  • CAR chimeric antigen receptor
  • the isolated monoclonal antibody or antigen-binding fragment thereof or antigen binding domain thereof of the invention comprises a heavy chain variable region having the polypeptide sequence at least 85%.
  • SEQ ID NO: 1 15, 29, 58, 72, 86, 100, 114, 128, or 142, and a light chain variable region having a polypeptide sequence at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 2, 16, 30, 59, 73, 87, 101, 115, 129, or 143, respectively.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or antigen binding domain thereof of the invention, comprising:
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1 , HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 3, 4, 5, 6, 7, and 8, respectively, or SEQ ID NOs: 9, 10, 11, 12, 13, and 14, respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:2.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 1; and a light chain variable region having the polypeptide sequence of SEQ ID NO:2.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1 , HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 17, 18, 19, 20, 21, and 22, respectively, or SEQ ID NOs: 23, 24. 25. 26. 27, and 28. respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%. 98%. or 99% identical to SEQ ID NO: 15, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 16.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 15; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 16.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 31, 32, 33, 34, 35, and 36, respectively, or SEQ ID NOs: 37, 38. 39. 40, 41, and 42. respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:29, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:30.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO:29; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 30.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 60, 61, 62, 63, 64, and 65, respectively, or SEQ ID NOs: 66, 67. 68. 69, 70, and 71. respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:58, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:59.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO:58; and a light chain variable region having the polypeptide sequence of SEQ ID NO:59.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. and LCDR3. having the polypeptide sequences of SEQ ID NOs: 74, 75, 76, 77, 78, and 79, respectively, or SEQ ID NOs: 80, 81. 82. 83. 84. and 85. respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%. 96%. 97%. 98%. or 99% identical to SEQ ID NO: 72, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:73.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO:72; and a light chain variable region having the polypeptide sequence of SEQ ID NO:73.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. and LCDR3, having the polypeptide sequences of SEQ ID NOs: 88, 89, 90, 91, 92, and 93, respectively, or SEQ ID NOs: 94, 95. 96. 97. 98. and 99. respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%. 96%. 97%. 98%. or 99% identical to SEQ ID NO: 86, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 87.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 86; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 87.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. and LCDR3, having the polypeptide sequences of SEQ ID NOs: 102, 103, 104, 105.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 100, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 101.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 100; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 101.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 116, 117, 118, 119, 120, and 121, respectively, or SEQ ID NOs: 122, 123, 124, 125, 126, and 127, respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 114, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 115.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 114; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 115.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1 , HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 130, 131, 132, 133, 134, and 135, respectively, or SEQ ID NOs: 136, 137, 138, 139, 140, and 141, respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 128, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%. 96%. 97%. 98%. or 99% identical to SEQ ID NO: 129.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 128; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 129.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2. and LCDR3. having the polypeptide sequences of SEQ ID NOs: 144, 145. 146, 147. 148, and 149, respectively, or SEQ ID NOs: 150, 151, 152. 153, 154, and 155, respectively.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 142, and a light chain variable region having a polypeptide sequence at least 85%, preferably 90%, more preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 143.
  • the isolated monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 142; and a light chain variable region having the polypeptide sequence of SEQ ID NO: 143.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain of the invention, wherein the antibody or antigen-binding fragment thereof or the antigenbinding domain is chimeric.
  • the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain of the invention, wherein the antibody or antigen-binding fragment thereof or the antigenbinding domain is human or humanized.
  • the humanized monoclonal antibody or antigen-binding fragment thereof or the humanized antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 43-50, or a light chain variable region having a polypeptide sequence at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 1-57.
  • the humanized monoclonal antibody or antigen-binding fragment thereof or the antigen-binding domain comprises: (1) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:43, and a light chain variable region having the polypeptide sequence of SEQ ID NO:51;
  • (21) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:45, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 57;
  • (31) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 53;
  • (32) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 54;
  • the antigen binding domain is a single chain variable fragment (scFv).
  • the encoded antigen binding domain is a humanized single chain variable fragment (scFv).
  • the chimeric antigen receptor comprises one or more antigen binding domains.
  • the intracellular signaling domain comprises one or more costimulatoiy domains and one or more activating domains.
  • the invention relates to an isolated nucleic acid encoding a monoclonal antibody or antigen-binding fragment thereof and/or a bispecific antibody or antigen-binding fragment thereof of the invention.
  • the invention relates to an isolated polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain thereof of the invention.
  • CAR chimeric antigen receptor
  • the coding sequence of a protein can be changed (e.g., replaced, deleted, inserted, etc.) without changing the amino acid sequence of the protein.
  • nucleic acid sequences encoding monoclonal antibodies or antigen-binding fragments thereof of the invention can be altered without changing the amino acid sequences of the proteins.
  • the invention in another general aspect, relates to a vector comprising an isolated nucleic acid encoding a monoclonal antibody or antigen-binding fragment thereof, a bispecific antibody or antigen-binding fragment thereof, and/or a CAR of the invention.
  • Any vector known to those skilled in the art in view of the present disclosure can be used, such as a plasmid, a cosmid, a phage vector, or a viral vector.
  • the vector is a recombinant expression vector such as a plasmid.
  • the vector can include any element to establish a conventional function of an expression vector, for example, a promoter, ribosome binding element, terminator, enhancer, selection marker, and origin of replication.
  • the promoter can be a constitutive, inducible, or repressible promoter.
  • a number of expression vectors capable of delivering nucleic acids to a cell are known in the art and can be used herein for production of an antibody or antigen-binding fragment thereof in the cell. Conventional cloning techniques or artificial gene synthesis can be used to generate a recombinant expression vector according to embodiments of the invention.
  • the invention relates to a host cell comprising an isolated nucleic acid encoding a monoclonal antibody or antigen-binding fragment thereof and/or a bispecific antibody or antigen-binding fragment thereof of the invention.
  • Any host cell know n to those skilled in the art in view of the present disclosure can be used for recombinant expression of antibodies or antigen-binding fragments thereof of the invention.
  • the host cells are E. coli TGI or BL21 cells (for expression of, e.g., an scFv or Fab antibody), CHO-DG44 or CHO-K1 cells or HEK293 cells (for expression of, e.g., a full-length IgG antibody).
  • the recombinant expression vector is transformed into host cells by conventional methods such as chemical transfection, heat shock, or electroporation, where it is stably integrated into the host cell genome such that the recombinant nucleic acid is effectively expressed.
  • the invention in another general aspect, relates to a method of producing a monoclonal antibody or antigen-binding fragment thereof and/or a bispecific antibody or antigen-binding fragment thereof of the invention, comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof under conditions to produce a monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigenbinding fragment thereof of the invention, and recovering the antibody or antigen-binding fragment thereof from the cell or cell culture (e.g., from the supernatant).
  • Expressed antibodies or antigen-binding fragments thereof can be harvested from the cells and purified according to conventional techniques known in the art and as described herein.
  • the invention in another general aspect, relates to a cell transduced with the vector comprising the isolated nucleic acids encoding the CARs of the invention.
  • transduced refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
  • a “transduced” cell is one which has been transduced with exogenous nucleic acid.
  • the cell includes the primary subject cell and its progeny.
  • the cell is a CAR-T cell, preferably a human CAR-T cell, wherein the T cell is engineered to express the CAR of the invention to treat diseases such as cancer.
  • the cell is a CAR-NK cell, preferably a human CAR-NK cell, wherein the NK cell engineered to express the CAR of the invention is used to treat diseases such as cancer.
  • the invention relates to a method of making a CAR-T cell by transducing a T cell with a vector comprising the isolated nucleic acids encoding the CARs of the invention.
  • the invention in another general aspect, relates to a method of producing the CAR-T cell thereof of the invention, comprising culturing T cells comprising a nucleic acid encoding a chimeric antigen receptor (CAR) of the invention under conditions to produce the CAR-T cell, and recovering the CAR-T cell.
  • CAR chimeric antigen receptor
  • the invention relates to a method of making a CAR-NK cell by transducing aNK cell with a vector comprising the isolated nucleic acids encoding the CARs of the invention.
  • the invention in another general aspect, relates to a method of producing a CAR-NK cell of the invention, comprising culturing NK cells comprising nucleic acids encoding the chimeric antigen receptor (CAR) thereof under conditions to produce the CAR-NK cell, and recovering the CAR-NK cell.
  • CAR chimeric antigen receptor
  • the invention in another general aspect, relates to a method of generating a population of RNA-engineered cells comprising a chimeric antigen receptor (CAR) of the invention.
  • the methods comprise contacting a population of cells with isolated polynucleotides comprising a nucleic acid encoding a CAR of the invention, wherein the isolated polynucleotides are in vitro transcribed RNA or synthetic RNA.
  • the invention in another general aspect, relates to a pharmaceutical composition, comprising an isolated monoclonal antibody or antigen-binding fragment thereof, a bispecific antibody or antigen-binding fragment thereof, an isolated polynucleotide, an isolated polypeptide, a host cell, and/or an engineered immune cell of the invention and a pharmaceutically acceptable carrier.
  • compositions means a product comprising an isolated polynucleotide of the invention, an isolated polypeptide of the invention, a host cell of the invention, an engineered immune cell of the invention, an anti-RORl monoclonal antibody or antigen-binding fragment thereof, and/or a bispecific antibody of the invention together with a pharmaceutically acceptable carrier.
  • Polynucleotides, polypeptides, host cells, engineered immune cells of the invention, an anti-RORl monoclonal antibody or antigen-binding fragment thereof, and/or a bispecific antibody of the invention and compositions comprising them are also useful in the manufacture of a medicament for therapeutic applications mentioned herein.
  • carrier refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle, microsphere, liposomal encapsulation, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient or diluent will depend on the route of administration for a particular application.
  • pharmaceutically acceptable carrier refers to a non-toxic material that does not interfere with the effectiveness of a composition according to the invention or the biological activity of a composition according to the invention. According to particular embodiments, in view- of the present disclosure, any pharmaceutically acceptable carrier suitable for use in an antibody pharmaceutical composition can be used in the invention.
  • the formulation of pharmaceutically active ingredients with pharmaceutically acceptable carriers is known in the art, e.g., Remington: The Science and Practice of Pharmacy (e.g., 21st edition (2005), and any later editions).
  • additional ingredients include buffers, diluents, solvents, tonicity regulating agents, preservatives, stabilizers, and chelating agents.
  • One or more pharmaceutically acceptable carrier(s) can be used in formulating the pharmaceutical compositions of the invention.
  • the pharmaceutical composition is a liquid formulation.
  • a preferred example of a liquid formulation is an aqueous formulation, i.e., a formulation comprising water.
  • the liquid formulation can comprise a solution, a suspension, an emulsion, a microemulsion, a gel, and the like.
  • An aqueous formulation typically comprises at least 50% w/w water, or at least 60%, 70%, 75%, 80%, 85%, 90%, or at least 95% w/w of water.
  • the pharmaceutical composition can be formulated as an injectable which can be injected, for example, via an injection device (e.g., a syringe or an infusion pump).
  • the injection can be delivered subcutaneously, intramuscularly, intraperitoneally, intravitreally, or intravenously, for example.
  • the pharmaceutical composition is a solid formulation, e.g., a freeze-dried or spray-dried composition, which can be used as is, or whereto the physician or the patient adds solvents, and/or diluents prior to use.
  • Solid dosage forms can include tablets, such as compressed tablets, and/or coated tablets, and capsules (e.g., hard or soft gelatin capsules).
  • the pharmaceutical composition can also be in the form of sachets, dragees, powders, granules, lozenges, or powders for reconstitution, for example.
  • the dosage forms may be immediate release, in which case they can comprise a water-soluble or dispersible carrier, or they can be delayed release, sustained release, or modified release, in which case they can comprise water-insoluble polymers that regulate the rate of dissolution of the dosage form in the gastrointestinal tract or under the skin.
  • the pharmaceutical composition can be delivered intranasally, intrabuccally, or sublingually.
  • the pH in an aqueous formulation can be between pH 3 and pH 10.
  • the pH of the formulation is from about 7.0 to about 9.5. In another embodiment of the invention, the pH of the formulation is from about 3.0 to about 7.0.
  • the pharmaceutical composition comprises a buffer.
  • buffers include: arginine, aspartic acid, bicine, citrate, disodium hydrogen phosphate, fumaric acid, glycine, glycylglycine, histidine, lysine, maleic acid, malic acid, sodium acetate, sodium carbonate, sodium dihydrogen phosphate, sodium phosphate, succinate, tartaric acid, tricine, and tris(hydroxymethyl)-aminomethane, and mixtures thereof.
  • the buffer can be present individually or in the aggregate, in a concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about 0. 1 mg/ml to about 20 mg/ml. Pharmaceutical compositions comprising each one of these specific buffers constitute alternative embodiments of the invention.
  • the pharmaceutical composition comprises a preservative.
  • preservatives include: benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butyl 4-hydroxybenzoate, chlorobutanol, chlorocresol, chlorohexidine, chlorphenesin, o-cresol, m-cresol, p-cresol, ethyl 4- hydroxybenzoate, imidurea, methyl 4-hydroxybenzoate, phenol, 2-phenoxyethanol, 2- phenylethanol, propyl 4-hydroxybenzoate, sodium dehydroacetate, thiomerosal, and mixtures thereof.
  • the preservative can be present individually or in the aggregate, in a concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about 0. 1 mg/ml to about 20 mg/ml.
  • Pharmaceutical compositions comprising each one of these specific preservatives constitute alternative embodiments of the invention.
  • the pharmaceutical composition comprises an isotonic agent.
  • isotonic agents include a salt (such as sodium chloride), an amino acid (such as glycine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, and threonine), an alditol (such as glycerol, 1.2-propanediol propyleneglycol), 1,3 -propanediol, and 1,3-butanediol), polyethyleneglycol (e.g., PEG400), and mixtures thereof.
  • a salt such as sodium chloride
  • amino acid such as glycine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, and threonine
  • alditol such as glycerol, 1.2-propanediol propyleneglycol
  • Non-limiting examples of sugars may be mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrm, alpha and beta-HPCD, soluble starch, hydroxyethyl starch, and sodium carboxymethylcellulose.
  • Another example of an isotonic agent is a sugar alcohol, wherein the term “sugar alcohol” is defined as a C(4-8) hydrocarbon having at least one -OH group.
  • Non-limiting examples of sugar alcohols include mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol.
  • the isotonic agent can be present individually or in the aggregate, in a concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about 0. 1 mg/ml to about 20 mg/ml.
  • Pharmaceutical compositions comprising each one of these specific isotonic agents constitute alternative embodiments of the invention.
  • the pharmaceutical composition comprises a chelating agent.
  • chelating agents include citric acid, aspartic acid, salts of ethylenediaminetetraacetic acid (EDTA), and mixtures thereof.
  • the chelating agent can be present individually or in the aggregate, in a concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about 0. 1 mg/ml to about 20 mg/ml.
  • Pharmaceutical compositions comprising each one of these specific chelating agents constitute alternative embodiments of the invention.
  • the pharmaceutical composition comprises a stabilizer.
  • stabilizers include one or more aggregation inhibitors, one or more oxidation inhibitors, one or more surfactants, and/or one or more protease inhibitors.
  • the pharmaceutical composition comprises a stabilizer, wherein said stabilizer is carboxy-Zhydroxy cellulose and derivatives thereof (such as HPC, HPC-SL, HPC-L and HPMC), cyclodextrins. 2-methylthioethanol, polyethylene glycol (such as PEG 3350), polyvinyl alcohol (PVA), polyvinyl pyrrolidone, salts (such as sodium chloride), sulphur-containing substances such as monothioglycerol), or thioglycolic acid.
  • the stabilizer can be present individually or in the aggregate, in a concentration from about 0.01 mg/ml to about 50 mg/ml, for example from about 0.1 mg/ml to about 20 mg/ml.
  • compositions comprising each one of these specific stabilizers constitute alternative embodiments of the invention.
  • the pharmaceutical composition comprises one or more surfactants, preferably a surfactant, at least one surfactant, or two different surfactants.
  • surfactant refers to any molecules or ions that are comprised of a water-soluble (hydrophilic) part, and a fat-soluble (lipophilic) part.
  • the surfactant can, for example, be selected from the group consisting of anionic surfactants, cationic surfactants, nonionic surfactants, and/or zwitterionic surfactants.
  • the surfactant can be present individually or in the aggregate, in a concentration from about 0.1 mg/ml to about 20 mg/ml.
  • Pharmaceutical compositions comprising each one of these specific surfactants constitute alternative embodiments of the invention.
  • the pharmaceutical composition comprises one or more protease inhibitors, such as. e.g., EDTA, and/or benzamidine hydrochloric acid (HC1).
  • the protease inhibitor can be present individually or in the aggregate, in a concentration from about 0. 1 mg/ml to about 20 mg/ml.
  • Pharmaceutical compositions comprising each one of these specific protease inhibitors constitute alternative embodiments of the invention.
  • the invention in another general aspect, relates to a method of producing a pharmaceutical composition comprising a monoclonal antibody or antigen-binding fragment thereof and/or a bispecific antibody or antigen-binding fragment thereof of the invention, comprising combining a monoclonal antibody or antigen-binding fragment thereof and/or a bispecific antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.
  • the invention in another general aspect, relates to a method of targeting ROR1 on a cancer cell surface in a subject to achieve cell killing, the method comprising administering to the subject an isolated monoclonal antibody or antigen binding fragment thereof and/or bispecific antibody or antigen-binding fragment thereof that specifically binds ROR1 or a pharmaceutical composition comprising the isolated monoclonal antibody or antigen binding fragment thereof and/or bispecific antibody or antigen-binding fragment thereof of the invention.
  • Binding of the ROR1 monoclonal or bispecific antibody or antigen-binding fragment to ROR1 can mediate complement-dependent cytotoxicity (CDC), antibodydependent cellular phagocytosis (ADCP), and/or antibody-dependent cellular cytotoxicity (ADCC) or other effects that result in the death of the targeted cancer cell.
  • the monoclonal or bispecific antibody or antigen binding fragment thereof can, for example, serve to recruit conjugated drugs, and/or can form a bispecific antibody with another monoclonal antibody to mediate the death of the targeted cancer cell.
  • the functional activity of antibodies and antigen-binding fragments thereof that bind ROR1 can be characterized by methods known in the art and as described herein.
  • Methods for characterizing antibodies and antigen-binding fragments thereof that bind ROR1 include, but are not limited to, affinity and specificity’ assays including Biacore, ELISA, OctetRed and GatorBio analysis, and detection of the binding of antibodies and antigen-binding fragments to ROR1 on cells (either cells transfected with ROR1 or cells that naturally express ROR1) by FACS.
  • the methods for characterizing antibodies and antigen-binding fragments thereof that bind ROR1 include those described below.
  • the invention in another general aspect, relates to a method of treating a cancer in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof and/or bispecific antibody or antigen-binding fragment thereof that specifically binds ROR1 or a pharmaceutical composition of the invention.
  • the cancer can, for example, be selected from but not limited to, a lung cancer, a gastric cancer, an esophageal cancer, a bile duct cancer, a cholangiocarcinoma, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a chronic myelogenous leukemia (CML), a multiple myeloma (MM), an acute myeloid leukemia (AML), and other liquid tumors.
  • the invention relates to a method of treating an inflammatory’ and/or autoimmune disease in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof and/or bispecific antibody or antigen-binding fragment thereof that specifically binds ROR1 or a pharmaceutical composition of the invention.
  • the invention relates to a method of treating a cancer in a subject in need thereof, comprising administering to the subject the CAR-T cells and/or CAR-NK cells of the invention.
  • the cancer can, for example, be selected from but not limited to, a lung cancer, a gastric cancer, an esophageal cancer, a bile duct cancer, a cholangiocarcinoma, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic leukemia (ALL), a chronic lymphocytic
  • NHL acute lympho
  • the CAR-T cell or CAR-NK cells comprise a therapeutically effective amount of the expressed CARs of the invention and the pharmaceutical composition comprises a therapeutically effective amount of an anti-RORl antibody or antigen-binding fragment thereof (e g., anti-RORl antibody).
  • an anti-RORl antibody or antigen-binding fragment thereof e g., anti-RORl antibody
  • the term ‘‘therapeutically effective amount” refers to an amount of an active ingredient or component that elicits the desired biological or medicinal response in a subject.
  • a therapeutically effective amount can be determined empirically and in a routine manner, in relation to the stated purpose.
  • a therapeutically effective amount means an amount of the CAR molecule expressed in the transduced T cell or NK cell that modulates an immune response in a subject in need thereof. Also, as used herein with reference to CARs, a therapeutically effective amount means an amount of the CAR molecule expressed in the transduced T cell or NK cell that results in treatment of a disease, disorder, or condition; prevents or slows the progression of the disease, disorder, or condition; or reduces or completely alleviates symptoms associated with the disease, disorder, or condition.
  • a therapeutically effective amount means an amount of the CAR-T cells or CAR-NK cells that modulates an immune response in a subject in need thereof. Also, as used herein with reference to CAR-T cell or CAR-NK cell, a therapeutically effective amount means an amount of the CAR-T cells or CAR-NK cells that results in treatment of a disease, disorder, or condition; prevents or slows the progression of the disease, disorder, or condition; or reduces or completely alleviates symptoms associated with the disease, disorder, or condition.
  • a therapeutically effective amount means an amount of the anti-RORl antibody or antigen-binding fragment thereof that modulates an immune response in a subject in need thereof. Also, as used herein with reference to anti-RORl antibodies or antigen-binding fragments thereof, a therapeutically effective amount means an amount of the anti-RORl antibody or antigen-binding fragment thereof that results in treatment of a disease, disorder, or condition; prevents or slows the progression of the disease, disorder, or condition; or reduces or completely alleviates symptoms associated with the disease, disorder, or condition.
  • the disease, disorder or condition to be treated is cancer, preferably a cancer selected from the group consisting of a lung cancer, a gastric cancer, an esophageal cancer, a bile duct cancer, a cholangiocarcinoma, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a chronic myelogenous leukemia (CML), a multiple myeloma (MM), an acute lymphoma (NHL), an
  • a therapeutically effective amount refers to the amount of therapy which is sufficient to achieve one, two, three, four, or more of the following effects: (i) reduce or ameliorate the severity of the disease, disorder or condition to be treated or a symptom associated therewith; (ii) reduce the duration of the disease, disorder or condition to be treated, or a symptom associated therewith; (hi) prevent the progression of the disease, disorder or condition to be treated, or a symptom associated therewith; (iv) cause regression of the disease, disorder or condition to be treated, or a symptom associated therewith; (v) prevent the development or onset of the disease, disorder or condition to be treated, or a symptom associated therewith; (vi) prevent the recurrence of the disease, disorder or condition to be treated, or a symptom associated therewith; (vii) reduce hospitalization of a subject having the disease, disorder or condition to be treated, or a symptom associated therewith; (viii) reduce hospitalization length of a subject having the disease
  • the therapeutically effective amount or dosage can vary according to various factors, such as the disease, disorder or condition to be treated, the means of administration, the target site, the physiological state of the subject (including, e.g., age, body weight, health), whether the subject is a human or an animal, other medications administered, and whether the treatment is prophylactic or therapeutic. Treatment dosages are optimally titrated to optimize safety and efficacy.
  • the compositions described herein are formulated to be suitable for the intended route of administration to a subject.
  • the compositions described herein can be formulated to be suitable for intravenous, subcutaneous, or intramuscular administration.
  • the cells of the invention can be administered in any convenient manner known to those skilled in the art.
  • the cells of the invention can be administered to the subject by aerosol inhalation, injection, ingestion, transfusion, implantation, and/or transplantation.
  • the compositions comprising the cells of the invention can be administered transarterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intrapleurally, by intravenous (i.v.) injection, or intraperitoneally.
  • the cells of the invention can be administered with or without lymphodepletion of the subject.
  • compositions comprising cells expressing CARs of the invention can be provided in sterile liquid preparations, typically isotonic aqueous solutions with cell suspensions, or optionally as emulsions, dispersions, or the like, which are typically buffered to a selected pH.
  • the compositions can comprise earners, for example, water, saline, phosphate buffered saline, and the like, suitable for the integrity and viability of the cells, and for administration of a cell composition.
  • Sterile injectable solutions can be prepared by incorporating cells of the invention in a suitable amount of the appropriate solvent with various other ingredients, as desired.
  • Such compositions can include a pharmaceutically acceptable carrier, diluent, or excipient such as sterile w ater, physiological saline, glucose, dextrose, or the like, that are suitable for use with a cell composition and for administration to a subject, such as a human.
  • Suitable buffers for providing a cell composition are well known in the art. Any vehicle, diluent, or additive used is compatible with preserving the integrity and viability of the cells of the invention.
  • the cells of the invention can be administered in any physiologically acceptable vehicle.
  • a cell population comprising cells of the invention can comprise a purified population of cells.
  • the ranges in purity in cell populations comprising genetically modified cells of the invention can be from about 50% to about 55%, from about 55% to about 60%, from about 60% to about 65%, from about 65% to about 70%, from about 70% to about 75%, from about 75% to about 80%, from about 80% to about 85%, from about 85% to about 90%, from about 90% to about 95%, or from about 95% to about 100%. Dosages can be readily adjusted by those skilled in the art, for example, a decrease in purity could require an increase in dosage.
  • the cells of the invention are generally administered as a dose based on cells per kilogram (cells/kg) of body weight of the subject to which the cells are administered.
  • the cell doses are in the range of about 10 4 to about 10 10 cells/kg of body weight, for example, about 10 5 to about 10 9 , about 10 5 to about 10 8 , about 10 5 to about 10 7 , or about 10 5 to about 10 6 , depending on the mode and location of administration.
  • a higher dose is used than in regional administration, where the immune cells of the invention are administered in the region of a tumor and/or cancer.
  • Exemplary dose ranges include, but are not limited to, 1 x 10 4 to l x 10 8 , 2 x 10 4 to 1 x 10 8 , 3 x 10 4 to 1 x 10 8 , 4 x 10 4 to 1 x 10 8 , 5 x 10 4 to 6 x 10 8 , 7 x 10 4 to 1 x 10 8 , 8 x 10 4 to 1 x 10 8 .
  • the terms “treat,” “treating.” and “treatment” are all intended to refer to an amelioration or reversal of at least one measurable physical parameter related to a cancer, an inflammatory and/or autoimmune disease, disorder or condition, which is not necessarily discernible in the subject, but can be discernible in the subject.
  • the terms “treat,” “treating.” and “treatment,” can also refer to causing regression, preventing the progression, or at least slowing dow n the progression of the disease, disorder, or condition.
  • “treat,” “treating,” and “treatment” refer to an alleviation, prevention of the development or onset, or reduction in the duration of one or more symptoms associated with the disease, disorder, or condition, such as a tumor or more preferably a cancer.
  • “treat,” “treating,” and “treatment” refer to prevention of the recurrence of the disease, disorder, or condition.
  • “treat,” “treating,” and “treatment” refer to an increase in the survival of a subject having the disease, disorder, or condition.
  • “treat,” “treating.” and “treatment” refer to elimination of the disease, disorder, or condition in the subject.
  • compositions used in the treatment of a cancer, an inflammatory and/or autoimmune disease, disorder or condition can be used in combination with another treatment including, but not limited to, a chemotherapy, an anti-CD20 mAb, an anti-TIM-3 mAb, an anti-LAG-3 mAb, an anti-EGFR mAb, an anti-HER-2 mAb, an anti-CD19 mAb, an anti-CD33 mAb, an anti-CD47 mAb, an anti-CD73 mAb, an anti-DLL-3 mAb, an anti-apelin mAb, an anti-FOLRl mAb, an anti-CTLA-4 mAb, an anti-PD-Ll mAb, an anti-PD-1 mAb, an anti-Claudin 18.2 mAb.
  • a chemotherapy an anti-CD20 mAb, an anti-TIM-3 mAb, an anti-LAG-3 mAb, an anti-EGFR mAb, an anti-HER-2 mAb, an anti-CD19
  • the methods of treating cancer in a subject in need thereof comprise administering to the subject the CAR-T cells and/or CAR-NK cells of the invention in combination with an agent that increases the efficacy of a cell expressing a CAR molecule.
  • agents include, but are not limited to, an antibody fragment that binds to CD73, CD39, PD1, PD-L1, PD-L2, CTLA4, TIM3 or LAG3. or an adenosine A2a receptor antagonist.
  • the methods of treating cancer in a subject in need thereof comprise administering to the subject the CAR-T cells and/or CAR-NK cells of the invention in combination with an agent that ameliorates one or more side effects associated with administration of a cell expressing a CAR molecule.
  • agents include, but are not limited to, a steroid, an inhibitor of TNFa, or an inhibitor of IL-6.
  • the methods of treating cancer in a subject in need thereof comprise administering to the subject the CAR-T cells and/or CAR-NK cells of the invention in combination with an agent that treats the disease associated with ROR1.
  • agents include, but are not limited to, an anti-RORl monoclonal antibody or bispecific antibody.
  • an combination in the context of the administration of two or more therapies to a subject, refers to the use of more than one therapy.
  • the use of the term “in combination” does not restrict the order in which therapies are administered to a subject.
  • a first therapy e.g..
  • a composition described herein can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 hours. 72 hours. 96 hours. 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy to a subject.
  • the invention in another general aspect, relates to a method of determining a level of ROR1 in a subject.
  • the methods comprise (a) obtaining a sample from the subject; (b) contacting the sample with a monoclonal antibody or antigen-binding fragment thereof of the invention; and (c) determining a level of ROR1 in the subject.
  • sample refers to a biological sample isolated from a subject and can include, but is not limited to, whole blood, serum, plasma, blood cells, endothelial cells, tissue biopsies (e.g., a cancer tissue), lymphatic fluid, ascites fluid, interstitial fluid, bone marrow, cerebrospinal fluid, saliva, mucous, sputum, sweat, urine, or any other secretion, excretion, or other bodily fluids.
  • tissue biopsies e.g., a cancer tissue
  • lymphatic fluid ascites fluid
  • interstitial fluid e.g., interstitial fluid
  • bone marrow e.g., a cancer tissue
  • cerebrospinal fluid e.g., saliva, mucous, sputum, sweat, urine, or any other secretion, excretion, or other bodily fluids.
  • a “blood sample” refers to whole blood or any fraction thereof, including blood cells, serum, and plasma.
  • the level of ROR1 in the subject can be determined utilizing assays selected from, but not limited to, a Western blot assay, immunohistochemistry (IHC) and an ELISA assay.
  • Relative protein levels can be determined by utilizing Western blot analysis and IHC, and absolute protein levels can be determined by utilizing an ELISA assay.
  • the levels of ROR1 can be determined between at least two samples, e.g., between samples from the same subject at different time points, between samples from different tissues in the same subject, and/or between samples from different subjects.
  • the absolute level of ROR1 in the sample can be determined by creating a standard for the ELISA assay prior to testing the sample.
  • analytical techniques to utilize to determine the level of ROR1 in a sample from the subject utilizing the antibodies or antigen-binding fragments thereof of the invention would understand which analytical techniques to utilize to determine the level of ROR1 in a sample from the subject utilizing the antibodies or antigen-binding fragments thereof of the invention.
  • Utilizing methods of determining a level of ROR1 in a sample from a subject can lead to the diagnosis of abnormal (elevated, reduced, or insufficient) ROR1 levels in a disease and making appropriate therapeutic decisions.
  • a disease can be selected from, but not limited to, a cancer, an inflammatory disease, or an autoimmune disease.
  • the risk of developing a disease as indicated above can be determined based on the knowledge of the level of ROR1 in a particular disease and/or during the progression of the particular disease.
  • Embodiment 1 is an isolated monoclonal antibody or antigen-binding fragment thereof or an antigen-binding domain comprising a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:
  • SEQ ID NOs: 144, 145, 146, 147, 148, and 149 respectively, or SEQ ID NOs: 150, 151, 152, 153, 154, and 155, respectively; wherein the antibody or antigen-binding fragment or the antigen-binding domain thereof specifically binds ROR1, preferably specifically binds human ROR1.
  • Embodiment 2 is the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain of embodiment 1, comprising a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 1, 15, 29, 58, 72, 86, 100, 114, 128, or 142, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 2. 16. 30, 59, 73, 87, 101, 115, 129, or 143.
  • Embodiment 3 is the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain of embodiment 1 or 2, comprising
  • Embodiment 4 is the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain of any one of embodiments 1 -3, wherein the antibody or antigenbinding fragment or the antigen-binding domain thereof is chimeric and/or human or humanized.
  • Embodiment 5 is the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain of embodiment 4, wherein the humanized monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof comprises a heavy chain variable region having a polypeptide sequence at least 95% identical to any one of SEQ ID NOs: 43-50, or a light chain variable region having a polypeptide sequence at least 95% identical to any one of SEQ ID NOs: 51-57.
  • Embodiment 6 is the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof of embodiment 5, wherein the humanized monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof comprises:
  • (21) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:45, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 57;
  • (22) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:46, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 51 ;
  • (31) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 53;
  • (32) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 54;
  • Embodiment 7 is the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain of any one of embodiments 1-6, wherein the isolated antibody or antigen-binding fragment or the antigen-binding domain thereof is capable of inducing effector-mediated tumor cell lysis through antibody -dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC); and/or mediating the recruitment of conjugated drugs; and/or forming a bispecific antibody with another monoclonal antibody (mAb) or antigen-binding fragment thereof with cancer-killing effect.
  • ADCC antibody -dependent cellular cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • Embodiment 8 is an isolated bispecific antibody or antigen-binding fragment thereof or a bispecific antigen-binding domain comprising the monoclonal antibody or antigenbinding fragment or the antigen-binding domain thereof of any one of embodiments 1-7.
  • Embodiment 9 is an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment or the antigen-binding domain of any one of embodiments 1 -7 or the bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain of embodiment 8.
  • Embodiment 10 is a vector comprising the isolated nucleic acid of embodiment 9.
  • Embodiment 11 is a host cell comprising the vector of embodiment 10.
  • Embodiment 12 is a pharmaceutical composition, comprising the isolated monoclonal antibody or antigen-binding fragment or the antigen-binding domain of any one of embodiments 1-7 or the bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof of embodiment 8 and a pharmaceutically acceptable carrier.
  • Embodiment 13 is a method of targeting ROR1 on a cancer cell surface, and/or treating a cancer, treating an inflammatory disease, and/or treating an autoimmune disease, in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of embodiment 12, optionally, wherein the cancer is selected from the group consisting of a lung cancer, a gastric cancer, an esophageal cancer, a bile duct cancer, a cholangiocarcinoma, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic
  • Embodiment 14 is a method of producing the monoclonal antibody or antigenbinding fragment or the antigen-binding domain of any one of embodiments 1 -7 or the bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof of embodiment 8, comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof or bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof under conditions to produce the monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof or bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof and recovering the monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof or bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof from the cell or culture.
  • Embodiment 15 is a method of producing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof of any one of embodiments 1-7 or the bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof of embodiment 8, comprising combining the monoclonal antibody or antigen-binding fragment or the antigen-binding domain thereof or bispecific antibody or antigen-binding fragment or the bispecific antigen-binding domain thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.
  • Embodiment 16 is a method of determining the level of ROR1 in a subject, the method comprising:
  • Embodiment 17 is the method of embodiment 16, wherein the sample is a tissue sample or a blood sample, optionally wherein the tissue sample is a cancer tissue sample.
  • Embodiment 18 is an isolated polynucleotide comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises:
  • Embodiment 19 is the isolated polynucleotide of embodiment 18, wherein the antigen binding domain comprises a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region comprising a light chain complementarity 7 determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:
  • Embodiment 20 is the isolated polynucleotide of embodiment 18 or 19, wherein the antigen binding domain comprises a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 1 , 15, 29, 58, 72, 86, 100, 114, 128, 142, or 43-50, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 2, 16. 30, 59, 73, 87, 101, 115, 129, 143, or 51-57.
  • Embodiment 21 is the isolated polynucleotide of embodiment 20, wherein the antigen binding domain comprises:
  • (21) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:44, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 54;
  • (22) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:44, and a light chain variable region having the polypeptide sequence of SEQ ID NO:55;
  • (31) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:45, and a light chain variable region having the polypeptide sequence of SEQ ID NO:57;
  • (41) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:47, and a light chain variable region having the polypeptide sequence of SEQ ID NO:53;
  • (61) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 50, and a light chain variable region having the polypeptide sequence of SEQ ID NO: 52;
  • (62) a heavy 7 chain variable region having the polypeptide sequence of SEQ ID NO: 50, and a light chain variable region having the polypeptide sequence of SEQ ID NO:53;
  • Embodiment 22 is the isolated polynucleotide of any one of embodiments 18-21, wherein the antigen binding domain is a single chain variable fragment (scFv).
  • scFv single chain variable fragment
  • Embodiment 23 is the isolated polynucleotide of embodiment 22, wherein the single chain variable fragment (scFv) is humanized.
  • Embodiment 24 is the isolated polynucleotide of any one of embodiments 18-23, wherein the chimeric antigen receptor (CAR) comprises one or more antigen binding domains, and/or wherein the intracellular signaling domain comprises one or more costimulatory domains and one or more activating domains.
  • CAR chimeric antigen receptor
  • Embodiment 25 is a chimeric antigen receptor (CAR) encoded by the isolated polynucleotide of any one of embodiments 18-24.
  • Embodiment 26 is a vector comprising the isolated polynucleotide of any one of embodiments 18-24.
  • Embodiment 27 is a host cell comprising the vector of embodiment 26, optionally, wherein the cell is a T cell or a NK cell, preferably a human T cell or a human NK cell.
  • Embodiment 28 is a method of making a host cell expressing a chimeric antigen receptor (CAR), the method comprising transducing a T cell or a NK cell with the vector of embodiment 26.
  • CAR chimeric antigen receptor
  • Embodiment 29 is a method of producing a chimeric antigen receptor (CAR)-T cell or a chimeric antigen receptor (CAR)-NK cell, the method comprising culturing T cells or NK cells comprising the isolated polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR) of any one of embodiments 18-24 under conditions to produce the CAR-T cell or CAR-NK cell and recovering the CAR-T cell or CAR-NK cell.
  • CAR chimeric antigen receptor
  • CAR chimeric antigen receptor
  • Embodiment 30 is a method of generating a cell comprising a chimeric antigen receptor (CAR), the method comprising contacting a cell with the isolated polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR) of any one of embodiments 18-24, wherein the isolated polynucleotide is an in vitro transcribed RNA or synthetic RNA.
  • CAR chimeric antigen receptor
  • Embodiment 31 is a method of treating cancer in a subject in need thereof, comprising administering to the subject in need thereof the host cell of embodiment 27, optionally wherein the cancer is selected from a lung cancer, a gastric cancer, an esophageal cancer, a bile duct cancer, a cholangiocarcinoma, a colon cancer, a hepatocellular carcinoma, a renal cell carcinoma, a bladder urothelial carcinoma, a metastatic melanoma, a breast cancer, an ovarian cancer, a cervical cancer, a head and neck cancer, a pancreatic cancer, a glioma, a glioblastoma, a mesothelioma, and other solid tumors, and a non-Hodgkin’s lymphoma (NHL), an acute lymphocytic leukemia (ALL), a chronic lymphocytic leukemia (CLL), a chronic myelogenous leukemia (CML
  • Embodiment 32 is the method of embodiment 31, further comprising administering to the subject in need thereof an agent that increases the efficacy of a cell expressing a CAR, or an agent that ameliorates one or more side effects associated with administration of a cell expressing a CAR, or an agent that treats the disease associated with ROR1.
  • VH heavy chain variable region
  • Table 2 Sequences of light chain variable regions for anti-RORl mAbs
  • VL light chain variable region
  • HC CDRs for the anti-RORl mAbs were determined utilizing the IMGT method (Lefranc, M.-P. et al., Nucleic Acids Res. 1999; 27:209-212).
  • Table 4 CDR regions 1-3 of light chain for anti-RORl mAbs
  • LC light chain
  • CDR complementarity detennining region
  • NO SEQ ID NO
  • the LC CDRs for the anti-RORl mAbs were determined utilizing the IMGT method (Lefranc, M.-P. et al., Nucleic Acids Res. 1999; 27:209-212).
  • HC heavy chain
  • CDR complementarity determining region
  • NO SEQ ID NO
  • the HC CDRs for the anti-RORl mAbs were determined utilizing the Kabat method (Elvin A. Kabat et al, Sequences of Proteins of Immunological Interest 5th ed. 1991).
  • LC light chain
  • CDR complementarity determining region
  • NO SEQ ID NO
  • the LC CDRs for the anti-RORl mAbs were determined utilizing the Kabat method (Elvin A. Kabat et al, Sequences ofProteins of Immunological Interest 5th ed. 1991).
  • Example 2 Production and purification of mAbs from culture media of transfected cells [00226]
  • the expression vectors containing the mouse variable regions (VH and VL) fused to the constant regions of human IgGl heavy chain and kappa light chain, respectively, were transiently transfected into ExpiCHO-S or Expi293F cells.
  • the recombinant antibodies produced in the supernatants of the ExpiCHO-S or Expi293F cell cultures were purified using Protein A affinity chromatography.
  • Protein A purified chimeric mAbs were tested in an ELISA assay for their ability to bind to immobilized ROR1 protein.
  • Recombinant human ROR1 ACROBiosy stems, CAT#: R01-H522y-100pg
  • DPBS buffer DPBS buffer
  • the plate was blocked by 5% BSA in TBST for 1 hour at room temperature.
  • the plate is washed with lx TBST.
  • Chimeric mAbs at various concentrations w ere added to each well and incubated for 1 hour at room temperature.
  • the plate was w ashed with lx TBST and the binding to ROR1 w as detected by mouse anti-human IgG Fc antibody (50B4A9) (Genescript, CAT#: AO 1854) with incubation for 1 hour at room temperature.
  • the plate was washed with lx TBST and ELISA was developed using 1-stepTM Ultra TMB-ELISA (ThermoFisher Scientific, CAT#: 34029) and measured the absorbance at 450nm. The results are shown in FIGs. 1A-1E.
  • the mouse anti-RORl mAbs w ere humanized to reduce the potential of immunogenicity when used in human patients.
  • the sequences of the variable regions of the heavy and light chains (VH and VL) were compared with the human antibody sequences in the Protein Data Bank (PDB) database and homology models were built.
  • the CDRs in both the heavy and light chains of the mouse mAbs were grafted into human frameworks that have the highest possibility of maintaining the proper structure likely required for antigen binding. Back mutations from human residues to mouse residue or other mutations were designed when necessary.
  • the sequences of the humanized VH and VL regions are shown in Table 7.
  • the humanized VH and VL regions were fused to the constant regions of human IgGl heavy chain and kappa light chain, respectively.
  • the binding of the humanized anti-RORl mAbs S7D12-H1L1, S7D12-H2LL S7D12-H4L2, S7D12-H4L3, S7D12-H5L4, S7D12-H6L5, S7D12-H7L6, S7D12-H7L7, S7D12-H8L6, and S7D12-H8L7 was assessed using ELISA (FIGs. 3A-3D).
  • S7D12-H1L1 refers to the humanized mAh constructed with S7D12-H1 heavy chain and S7D12-L1 light chain shown in Table 7; other humanized clones follow the same naming rule.
  • Example 6 Constructions of chimeric antigen receptor constructs comprising anti- mesothelin antigen binding domains
  • the mAbs are converted into scFvs using the VH, VL. and a (G4S)n linker, and the scFv is fused to the N-terminus of the hinge and transmembrane domains derived from human CD8a (aa 114-1 18, Boursier JP et al., J. Biol. Chem.
  • the C-terminal intracellular signaling domain of the CAR is constructed by fusing the intracellular costimulatory domain of CD28 (aa 162-202, Aruffo A and Seed B, Proc. Natl. Acad. Sci. USA 84(23):8573-7 (1987)) followed by the activation domain from CD3 zeta chain (aa 52-162, Letoumeur F and Klausner RD, Proc. Natl. Acad. Sci. USA 88(20):8905-9 (1991)).
  • the DNA sequence encoding the CAR is assembled and cloned into an expression vector (either retroviral, lentiviral, extrachromosomal or integrated) to generate the CAR construct using standard molecule biology cloning techniques.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Des anticorps anti-ROR1, des fragments de liaison à l'antigène de ceux-ci et des récepteurs antigéniques chimériques (CAR) comprenant des domaines de liaison à l'antigène anti-ROR1 sont décrits. L'invention concerne également des acides nucléiques codant pour les anticorps et les CAR, des compositions comprenant les anticorps et les cellules hôtes comprenant les CAR, des procédés de production des anticorps et des CAR, et des procédés d'utilisation des anticorps et des CAR pour traiter ou prévenir des maladies telles que le cancer et/ou une maladie inflammatoire, et/ou une maladie auto-immune.
PCT/US2023/075332 2022-10-03 2023-09-28 Anticorps anti-ror1 et leurs utilisations WO2024076864A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263378115P 2022-10-03 2022-10-03
US63/378,115 2022-10-03

Publications (2)

Publication Number Publication Date
WO2024076864A2 true WO2024076864A2 (fr) 2024-04-11
WO2024076864A3 WO2024076864A3 (fr) 2024-05-30

Family

ID=90608791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/075332 WO2024076864A2 (fr) 2022-10-03 2023-09-28 Anticorps anti-ror1 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2024076864A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044311A2 (fr) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Génération, caractérisation et utilisations d'anticorps anti-her3
WO2019217450A1 (fr) * 2018-05-08 2019-11-14 Rhode Island Hospital Anticorps anti-chi3l1 pour la détection et/ou le traitement d'une stéatose hépatique non alcoolique / stéatohépatite non alcoolique et des complications subséquentes

Also Published As

Publication number Publication date
WO2024076864A3 (fr) 2024-05-30

Similar Documents

Publication Publication Date Title
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
US20220184126A1 (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
US20220184127A1 (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
US20230220107A1 (en) Anti-Tumor Associated Antigen Antibodies and Uses Thereof
US20220162301A1 (en) Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
US20220305056A1 (en) Chimeric antigen receptor system and uses thereof
WO2024076864A2 (fr) Anticorps anti-ror1 et leurs utilisations
WO2024182475A2 (fr) Anticorps anti-ror2 et leurs utilisations
WO2024091870A2 (fr) Anticorps anti-egfrviii et leurs utilisations
WO2024102604A1 (fr) Anticorps anti-5t4 et leurs utilisations
AU2023218343A1 (en) Anti-il13ra2 antibodies and uses thereof
WO2023177974A2 (fr) Anticorps anti-mésothéline et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23875625

Country of ref document: EP

Kind code of ref document: A2